Low libido in menopause: what DHEA and testosterone actually do

What did @nancyychristine actually say?

She made three specific claims: that intrarosa (vaginal DHEA) improves dryness, pain, and libido locally; that over-the-counter DHEA cream improves sensitivity and desire with less research behind it; and that flibanserin (Addyi) targets low desire through brain mechanisms rather than hormones. She also gave an honest caveat upfront: "testosterone is the most effective treatment for low libido." That context matters and she included it, which is more than most TikTok menopause content does.

Her framing throughout was that women need to figure out whether their issue is physical, desire-based, or both before picking a treatment. That's not wrong. It's actually how clinicians are supposed to approach this.

Does the science back this up?

Mostly yes, with some caveats on the OTC DHEA claim. The intrarosa data is solid. The flibanserin characterization is accurate but incomplete. The OTC DHEA cream claim is the weakest leg of the stool.

Intrarosa (prasterone 6.5mg vaginal insert) was studied in the Endocrine Society trials and the pivotal FDA approval data showed statistically significant improvements in dyspareunia and vaginal atrophy, with secondary endpoints showing libido improvements. Labrie et al. (2016, Menopause) confirmed local androgenic and estrogenic activity with minimal systemic absorption, which is the key clinical selling point.

Flibanserin (Addyi) works as a serotonin 1A agonist and 2A antagonist, targeting neurotransmitter pathways rather than hormones. The characterization as brain-based is accurate. Katz et al. (2013, Journal of Sexual Medicine) showed modest but statistically significant improvements in satisfying sexual events in premenopausal women. The data in postmenopausal women is thinner, and she doesn't mention that.

OTC DHEA creams are where the evidence gets shaky. Simon et al. (2018, Menopause) noted that oral and transdermal DHEA bioavailability varies widely, formulations are unregulated, and most published studies used pharmaceutical-grade prasterone, not the creams sold at health stores. Calling this "same idea but less research" undersells how different it actually is.

What did they get wrong (or right)?

She got the intrarosa description right. It does work locally, it does have an effect on libido beyond just physical symptoms, and the no-generic cost issue is real. She got the Addyi description mostly right too. "Works on the brain, not hormones" is a fair plain-language summary of its mechanism.

The OTC DHEA cream framing is the problem. She says "same idea but less research," which implies the difference is just quantity of evidence. That's misleading. The actual issue is that over-the-counter DHEA products are not standardized, have inconsistent bioavailability, and have not been tested in controlled trials for sexual function specifically. It isn't a lesser version of intrarosa. It's a different product with a fundamentally weaker evidence profile and no regulatory oversight. That distinction needed to be clearer.

She also doesn't flag that flibanserin has a risk evaluation and mitigation strategy (REMS) program due to interactions with alcohol and certain medications. For a 29,000-view video recommending a prescription drug, that omission is notable.

What should you actually know?

If you're in perimenopause or menopause and dealing with low libido, the clinical picture is almost always a mix of hormonal, physical, and psychological factors. No single drug fixes all of them, and the creator is right that you have to identify the primary problem first.

Intrarosa is a reasonable option if vaginal dryness and pain are your main complaints alongside low desire. It keeps systemic hormone exposure low, which matters if you have contraindications to systemic estrogen or testosterone. The cost issue is real: without insurance coverage it can exceed $300 per month.

Addyi (flibanserin) has a modest effect size. A meta-analysis by Jaspers et al. (2016, JAMA Internal Medicine) found it increased satisfying sexual events by about 0.5 per month compared to placebo. That's statistically significant but clinically modest. It's not a home run. And the alcohol interaction is not optional fine print. The FDA requires a REMS program because combining flibanserin with alcohol can cause severe hypotension and syncope.

OTC DHEA cream should not be treated as a casual alternative to prescription options. Purity, dose, and absorption are all unknowns. If you want DHEA-based therapy, intrarosa is the version with actual regulatory review behind it.